Patient characteristics
| PT . | Gender . | Age, y . | Disease phase . | Material . | Blasts, % . | CD33MFI . | CD33 Tercile . | CD3, % . | FAB . | NPM1mut . | FLT3-ITD . | Karyotype . | ELN genetic group . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 60 | FD | BM | 95 | 5.3 | 1 | 1.9 | M4 | + | − | 46,XX | Favorable |
| 2 | F | 45 | FD | BM | 84 | 8.6 | 1 | 2.7 | M1 | + | + | 46,XX | Intermediate-I |
| 3 | M | 40 | FD | PB | 60 | 8.2 | 1 | 7.3 | M2 | − | − | 46,X,-Y,+8,t(8;21)(q22;q22) | Favorable |
| 4 | F | 43 | FD | PB | 96 | 22.9 | 1 | 1.2 | M3 | − | + | 46,XX,t(15;17)(q22;q21) | Favorable |
| 5 | M | 61 | FD | BM | 68 | 44.3 | 2 | 11.6 | M1 | − | − | inv(16)(p13),inv(16)(q22), del(7)(q22), +22 | Favorable |
| 6 | F | 54 | FD | PB | 61 | 58.4 | 2 | 12.7 | M1 | − | + | 46,XX | Intermediate-I |
| 7 | F | 69 | FD | PB | 88 | 31.8 | 2 | 5.6 | M1 | + | + | 46,XX,del(1) | Intermediate-II |
| 8 | F | 77 | Relapse | BM | 82 | 117.1 | 3 | 7.9 | M2 | + | − | 47,XX,+8 [4] / 46,XX [4] | Intermediate-II |
| 9 | F | 59 | FD | BM | 34 | 172.6 | 3 | 9.9 | M1 | − | − | 46,XX | Intermediate-I |
| 10 | F | 40 | FD | PB | 84 | 83.0 | 2 | 10.2 | M4 | + | + | 46,XX | Intermediate-I |
| 11 | M | 24 | FD | PB | 76 | 47.6 | 2 | 9.6 | M2 | − | − | 47,XY,+4[17]/46,XY[17] | Intermediate-II |
| 12 | M | 81 | FD | PB | 47 | 77.5 | 2 | 1.6 | M5 | + | − | 46,XY,der(10)t(3;10)(?;p1?) [3] / 47,sl,+8[4] | Adverse |
| 13 | F | 63 | Relapse | PB | 64 | 151.9 | 3 | 3.7 | M4 | + | + | 46,XX | Intermediate-I |
| PT . | Gender . | Age, y . | Disease phase . | Material . | Blasts, % . | CD33MFI . | CD33 Tercile . | CD3, % . | FAB . | NPM1mut . | FLT3-ITD . | Karyotype . | ELN genetic group . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 60 | FD | BM | 95 | 5.3 | 1 | 1.9 | M4 | + | − | 46,XX | Favorable |
| 2 | F | 45 | FD | BM | 84 | 8.6 | 1 | 2.7 | M1 | + | + | 46,XX | Intermediate-I |
| 3 | M | 40 | FD | PB | 60 | 8.2 | 1 | 7.3 | M2 | − | − | 46,X,-Y,+8,t(8;21)(q22;q22) | Favorable |
| 4 | F | 43 | FD | PB | 96 | 22.9 | 1 | 1.2 | M3 | − | + | 46,XX,t(15;17)(q22;q21) | Favorable |
| 5 | M | 61 | FD | BM | 68 | 44.3 | 2 | 11.6 | M1 | − | − | inv(16)(p13),inv(16)(q22), del(7)(q22), +22 | Favorable |
| 6 | F | 54 | FD | PB | 61 | 58.4 | 2 | 12.7 | M1 | − | + | 46,XX | Intermediate-I |
| 7 | F | 69 | FD | PB | 88 | 31.8 | 2 | 5.6 | M1 | + | + | 46,XX,del(1) | Intermediate-II |
| 8 | F | 77 | Relapse | BM | 82 | 117.1 | 3 | 7.9 | M2 | + | − | 47,XX,+8 [4] / 46,XX [4] | Intermediate-II |
| 9 | F | 59 | FD | BM | 34 | 172.6 | 3 | 9.9 | M1 | − | − | 46,XX | Intermediate-I |
| 10 | F | 40 | FD | PB | 84 | 83.0 | 2 | 10.2 | M4 | + | + | 46,XX | Intermediate-I |
| 11 | M | 24 | FD | PB | 76 | 47.6 | 2 | 9.6 | M2 | − | − | 47,XY,+4[17]/46,XY[17] | Intermediate-II |
| 12 | M | 81 | FD | PB | 47 | 77.5 | 2 | 1.6 | M5 | + | − | 46,XY,der(10)t(3;10)(?;p1?) [3] / 47,sl,+8[4] | Adverse |
| 13 | F | 63 | Relapse | PB | 64 | 151.9 | 3 | 3.7 | M4 | + | + | 46,XX | Intermediate-I |
FD, first diagnosis; PB, peripheral blood; BM, bone marrow.